Across TCGA pan-cancer cohorts, HSPB7 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated HSPB7 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher HSPB7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HSPB7 expression acts as an unfavorable survival marker.
SKCM and SARC are the cancer types where HSPB7 Mutation most reproducibly stratifies survival.